Compare MESO & AIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MESO | AIN |
|---|---|---|
| Founded | 2004 | 1895 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Textiles |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | N/A | 1987 |
| Metric | MESO | AIN |
|---|---|---|
| Price | $18.07 | $51.81 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 2 | 4 |
| Target Price | $24.00 | ★ $64.25 |
| AVG Volume (30 Days) | 211.8K | ★ 489.0K |
| Earning Date | 08-28-2025 | 11-05-2025 |
| Dividend Yield | N/A | ★ 2.15% |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $17,198,000.00 | ★ $1,148,512,000.00 |
| Revenue This Year | $465.44 | N/A |
| Revenue Next Year | $75.37 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 191.39 | N/A |
| 52 Week Low | $9.61 | $41.15 |
| 52 Week High | $22.00 | $83.65 |
| Indicator | MESO | AIN |
|---|---|---|
| Relative Strength Index (RSI) | 59.71 | 58.66 |
| Support Level | $16.43 | $49.13 |
| Resistance Level | $17.65 | $50.84 |
| Average True Range (ATR) | 0.61 | 1.45 |
| MACD | 0.24 | 1.00 |
| Stochastic Oscillator | 71.32 | 77.35 |
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
Albany International Corp is principally engaged in processing textiles and materials. The company consists of two business segments, the machine clothing segment, which produces and provides custom-designed fabrics and belts for the production in the paper, nonwovens, and other process industries; and the Albany engineered composites segment, which offers engineered composite parts for the aerospace and defensive industries. The machine clothing segment contributes to the majority of the company's total revenue. The company has an operation and generates revenue from the United States, Switzerland, Brazil, China, Mexico, France, and other areas.